50
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A new antibiotic with potent activity targets MscL

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The growing problem of antibiotic-resistant bacteria is a major threat to human health. Paradoxically, new antibiotic discovery is declining, with most of the recently approved antibiotics corresponding to new uses for old antibiotics or structurally similar derivatives of known antibiotics. We used an in silico approach to design a new class of nontoxic antimicrobials for the bacteria-specific mechanosensitive ion channel of large conductance, MscL. One antimicrobial of this class, compound 10, is effective against methicillin-resistant Staphylococcus aureus with no cytotoxicity in human cell lines at the therapeutic concentrations. As predicted from in silico modeling, we show that the mechanism of action of compound 10 is at least partly dependent on interactions with MscL. Moreover we show that compound 10 cured a methicillin-resistant S. aureus infection in the model nematode Caenorhabditis elegans. Our work shows that compound 10, and other drugs that target MscL, are potentially important therapeutics against antibiotic-resistant bacterial infections.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: not found
          • Article: not found

          Albumin: biochemical properties and therapeutic potential.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            New antibiotics from bacterial natural products.

            For the past five decades, the need for new antibiotics has been met largely by semisynthetic tailoring of natural product scaffolds discovered in the middle of the 20(th) century. More recently, however, advances in technology have sparked a resurgence in the discovery of natural product antibiotics from bacterial sources. In particular, efforts have refocused on finding new antibiotics from old sources (for example, streptomycetes) and new sources (for example, other actinomycetes, cyanobacteria and uncultured bacteria). This has resulted in several newly discovered antibiotics with unique scaffolds and/or novel mechanisms of action, with the potential to form a basis for new antibiotic classes addressing bacterial targets that are currently underexploited.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Antibiotics in the clinical pipeline in 2011.

              The emergence of multi-drug-resistant bacteria and the lack of new antibiotics in the antibiotic drug development pipeline, especially those with new modes of action, is a major health concern. This review lists the 20 new antibiotics launched since 2000 and records the 40 compounds currently in active clinical development. Compounds in the pipeline from new antibiotic classes are reviewed in detail with reference to their development status, mode of action, spectrum of activity and lead discovery. In addition, the NP or synthetic derivation is discussed, with activity against Gram-negative bacteria highlighted.
                Bookmark

                Author and article information

                Journal
                J Antibiot (Tokyo)
                J. Antibiot
                The Journal of Antibiotics
                Nature Publishing Group
                0021-8820
                1881-1469
                July 2015
                04 February 2015
                : 68
                : 7
                : 453-462
                Affiliations
                [1 ]Department of Physiology, UT Southwestern Med Ctr , Dallas, TX, USA
                [2 ]Department of Molecular Biology, Massachusetts General Hospital , Boston, MA, USA
                [3 ]Institute for Molecular Bioscience, University of Queensland , St Lucia, QLD, Australia
                [4 ]Department of Microbiology, Immunology, and Pathology, Colorado State University , Fort Collins, CO, USA
                [5 ]School of Animal Biology, The University of Western Australia , Crawley, WA, Australia
                [6 ]School of Biological Sciences, Flinders University, Bedford Park , SA, Australia
                [7 ]Flinders Medical Science and Technology, Immunology, Allergy and Arthritis, Flinders University, Bedford Park , SA, Australia
                [8 ]Centre for NanoScale Science and Technology, School of Chemical and Physical Sciences, Flinders University, Bedford Park , SA, Australia
                Author notes
                [* ]Centre for NanoScale Science and Technology, School of Chemical and Physical Sciences, Flinders University , Bedford Park, South Australia 5042, Australia. E-mail: Paul.blount@ 123456UTSouthwestern.edu or ramiz.boulos@ 123456flinders.edu.au
                Author information
                http://orcid.org/0000-0001-8936-430X
                http://orcid.org/0000-0003-4023-3506
                Article
                ja20154
                10.1038/ja.2015.4
                4430313
                25649856
                c80a5acb-857f-4287-b9f3-4148e420b3b8
                Copyright © 2015 Japan Antibiotics Research Association

                This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/

                History
                : 19 September 2014
                : 27 November 2014
                : 15 December 2014
                Categories
                Original Article

                Infectious disease & Microbiology
                Infectious disease & Microbiology

                Comments

                Comment on this article